Brokerages Set DaVita Inc. (NYSE:DVA) Price Target at $155.80

Shares of DaVita Inc. (NYSE:DVA) have earned an average recommendation of “Hold” from the seven analysts that are presently covering the firm, MarketBeat reports. One analyst has rated the stock with a sell recommendation, five have given a hold recommendation and one has assigned a buy recommendation to the company. The average 12-month price objective among brokers that have issued a report on the stock in the last year is $155.80.

Several analysts have issued reports on DVA shares. Zacks Research downgraded shares of DaVita from a “strong-buy” rating to a “hold” rating in a report on Monday, April 6th. UBS Group upped their price target on shares of DaVita from $186.00 to $190.00 and gave the company a “buy” rating in a report on Wednesday, February 4th. Truist Financial set a $158.00 price objective on shares of DaVita in a research note on Thursday, February 5th. TD Cowen reissued a “hold” rating on shares of DaVita in a research note on Tuesday, February 3rd. Finally, Wall Street Zen raised shares of DaVita from a “hold” rating to a “buy” rating in a research note on Saturday, February 21st.

Hedge Funds Weigh In On DaVita

Several institutional investors and hedge funds have recently modified their holdings of the company. Apollon Wealth Management LLC purchased a new position in shares of DaVita during the first quarter valued at approximately $217,000. Pictet Asset Management Holding SA lifted its stake in shares of DaVita by 9.1% during the first quarter. Pictet Asset Management Holding SA now owns 8,242 shares of the company’s stock valued at $1,267,000 after buying an additional 684 shares during the period. Louisiana State Employees Retirement System acquired a new position in DaVita during the first quarter worth approximately $261,000. Contravisory Investment Management Inc. acquired a new position in DaVita during the first quarter worth approximately $1,016,000. Finally, Kestra Private Wealth Services LLC acquired a new position in DaVita during the first quarter worth approximately $238,000. Hedge funds and other institutional investors own 90.12% of the company’s stock.

DaVita Trading Up 1.7%

DVA stock opened at $155.04 on Tuesday. The company has a market cap of $10.36 billion, a P/E ratio of 15.64, a P/E/G ratio of 0.53 and a beta of 0.92. DaVita has a 52 week low of $101.00 and a 52 week high of $159.42. The company’s 50-day moving average price is $150.87 and its 200 day moving average price is $130.58.

DaVita (NYSE:DVA) last announced its quarterly earnings results on Monday, February 2nd. The company reported $3.40 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.24 by $0.16. DaVita had a net margin of 5.47% and a negative return on equity of 413.18%. The company had revenue of $3.62 billion for the quarter, compared to the consensus estimate of $3.51 billion. During the same quarter in the prior year, the firm earned $2.24 earnings per share. The company’s revenue for the quarter was up 9.9% compared to the same quarter last year. DaVita has set its FY 2026 guidance at 13.600-15.00 EPS. On average, equities research analysts expect that DaVita will post 14.16 earnings per share for the current year.

DaVita Company Profile

DaVita Inc (NYSE: DVA) is a leading provider of kidney care services, specializing in the management and operation of outpatient dialysis centers for patients with chronic kidney failure and end-stage renal disease. Headquartered in Denver, Colorado, the company offers a comprehensive suite of treatment modalities, including in-center hemodialysis, peritoneal dialysis, and home dialysis therapies. In addition to its core dialysis services, DaVita provides patient education, nutritional counseling, vascular access management and related laboratory services to support kidney health and overall patient well-being.

Since its formation in the mid-1990s through a clinical management services spin-off, DaVita has expanded both organically and through strategic partnerships and acquisitions.